Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Follow-up Trial of GBS-NN/NN2 Vaccine in Pregnant Women
NCT06592586Phase 3Active, not recruiting
- Sponsor
- MinervaX
- Start
- Mar 2025
- Primary completion
- Jun 2029
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, open-label trial of GBS-NN/NN2 vaccine in Streptococcus agalactiae infection (GBS) (3 arms), sponsored by MinervaX. Primary endpoint: Concentration of IgG Antibodies to AlpN Proteins in Blood Serum at 4 years. Started Mar 2025; status: active, not recruiting.
02
Drugs
GBS-NN/NN2 vaccine
03
Conditions
Streptococcus agalactiae infection (GBS)
Beyond the preview
Go deeper on NCT06592586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06592586.